Company news

Pacira BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

November 5, 2025

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

November 4, 2025

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

November 3, 2025

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

October 29, 2025

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

October 27, 2025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

October 26, 2025

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

October 22, 2025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

October 20, 2025

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

October 19, 2025

Pacira BioSciences Reports Second Quarter 2025 Financial Results

August 4, 2025

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

July 23, 2025

Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts

July 21, 2025

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

June 17, 2025

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee

June 10, 2025

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

May 14, 2025

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

May 13, 2025

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 7, 2025

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

May 5, 2025

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 1, 2025

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

April 28, 2025

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

April 27, 2025

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

April 21, 2025

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

April 16, 2025

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

April 6, 2025

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

April 2, 2025

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

March 13, 2025

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

February 26, 2025

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

February 26, 2025

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

February 25, 2025

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

February 19, 2025

Pacira Announces Updates to Board of Directors

January 29, 2025

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

January 20, 2025

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

January 9, 2025

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

January 6, 2025

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 5, 2024

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

December 2, 2024

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

November 13, 2024

Pacira BioSciences Reports Third Quarter 2024 Financial Results

November 5, 2024

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

November 3, 2024

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

October 29, 2024

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

October 20, 2024

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

October 2, 2024

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

September 25, 2024

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

August 8, 2024

Pacira BioSciences Reports Second Quarter 2024 Financial Results

July 29, 2024

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

July 22, 2024

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

July 9, 2024

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

May 29, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.